
CytoHub, Inc. is a pioneering company at the forefront of cardiac drug discovery and regenerative medicine, specializing in AI-driven human mini-heart technology to revolutionize drug screening, disease modeling, and heart muscle regeneration. The company offers a comprehensive platform including advanced in vitro assays, iPSC-derived organoids and 3D cultures, organoids-on-chip technology, and primary cell-based assays to accelerate drug discovery and development of safe, effective therapies. CytoHub also provides services such as process development, bioreactor scale-up, analytical development, tech transfer, cell-line development, gene editing, and research development. Their AI-powered BioEngineAI platform enhances regenerative medicine development. With a strong leadership team and strategic advisors from industry and academia, CytoHub is positioned as an innovator in cell therapy and regenerative medicine biomanufacturing solutions, aiming to transform the landscape of cell therapy through cutting-edge technology and scientific expertise.

CytoHub, Inc. is a pioneering company at the forefront of cardiac drug discovery and regenerative medicine, specializing in AI-driven human mini-heart technology to revolutionize drug screening, disease modeling, and heart muscle regeneration. The company offers a comprehensive platform including advanced in vitro assays, iPSC-derived organoids and 3D cultures, organoids-on-chip technology, and primary cell-based assays to accelerate drug discovery and development of safe, effective therapies. CytoHub also provides services such as process development, bioreactor scale-up, analytical development, tech transfer, cell-line development, gene editing, and research development. Their AI-powered BioEngineAI platform enhances regenerative medicine development. With a strong leadership team and strategic advisors from industry and academia, CytoHub is positioned as an innovator in cell therapy and regenerative medicine biomanufacturing solutions, aiming to transform the landscape of cell therapy through cutting-edge technology and scientific expertise.
Headquarters: San Diego, California
Founded: 2023
Industry: Biotechnology
Focus: AI-driven human mini-heart platform for cardiac drug discovery and regenerative medicine
Employee count (reported): 13
Cardiac drug discovery, disease modeling, and regenerative medicine / cell therapy biomanufacturing.
2023
Biotechnology
Pre-Seed round listed on Crunchbase; amounts and investor names are obfuscated in public profile.